J&J agrees to sell LifeScan to Platinum Equity

13 June 2018 - Deborah Wilkes

Johnson & Johnson has agreed to sell its LifeScan blood glucose monitoring business to private-equity firm Platinum Equity for around USD2.1 billion.

LifeScan offers blood glucose monitoring systems for home and hospital use under its OneTouch brand. The business recorded sales of USD1.5 billion in 2017 from a portfolio of personal blood glucose meters, testing strips, lancets, point-of-care testing systems, and integrated digital systems.

Johnson & Johnson noted that LifeScan was the leading maker of blood glucose monitoring systems in the US, and its OneTouch brand products were recommended by more endocrinologists and primary care physicians than any other brand.

The transaction is expected to close by the end of 2018.

Johnson & Johnson announced in January 2017 that it was evaluating strategic options for its Diabetes Care businesses, including LifeScan (click here to read the News story).

Upgrade to an Annual Subscription to the OTCToolbox website, giving you UNLIMITED ACCESS to all of our publications
* OTCToolbox Innovations magazine NEW IDEAS BETTER WAYS
* OTCToolbox Deals Database
* Premium News Stories
* News Extras
* OTC Deal Trends Briefing
* OTC Company Strategies Report
Helping you and your company make well-informed decisions

Back to Industry News

Share this page: